Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Timber Pharmaceuticals Announces Merger Closing
Details : The combined company will have a robust pipeline including Timber's two Phase 2b programs and a preclinical program targeting multiple niche orphan indications with no approved treatments as well as BioPharmX's two Phase 3-ready topical minocycline progr...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
LOOKING FOR A SUPPLIER?